Naloxegol, marketed as Movantik, is a medication used to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain [1].
How does naloxegol work?
Naloxegol is a peripherally acting mu-opioid receptor antagonist (PAMORA) [1]. It works by blocking the effects of opioids on the mu-opioid receptors in the gastrointestinal tract. Opioids commonly cause constipation by slowing down bowel movements. Naloxegol is designed to relieve this constipation without interfering with the pain-relieving effects of opioids in the central nervous system [1].
When did naloxegol (Movantik) get approved?
Movantik received approval from the U.S. Food and Drug Administration (FDA) in September 2014 [1].
What are the potential side effects of Movantik?
Common side effects reported with Movantik include abdominal pain, diarrhea, nausea, and headache [1]. In rare cases, it can cause gastrointestinal events like bowel obstruction or perforation, particularly in individuals with underlying risk factors [1].
How does Movantik compare to other OIC treatments?
Other treatments for OIC include laxatives and other PAMORAs such as methylnaltrexone (Relistor) and naldemedine (Symproic) [2]. Movantik is taken orally once a day, while some other PAMORAs may require different dosing schedules or administration methods [2]. The choice of treatment often depends on individual patient factors, medical history, and physician recommendation.
When does the patent for Movantik expire?
Patent information for specific drugs can be complex and subject to various challenges and extensions. Information on patent expiry dates for Movantik and potential generic competition can be found through resources like DrugPatentWatch.com [3].
Who manufactures Movantik?
Movantik is manufactured by Red Hill Biopharma [4]. Previously, it was developed by AstraZeneca and Daiichi Sankyo.
What are the clinical trial results for naloxegol?
Clinical trials for Movantik demonstrated its efficacy in improving bowel movement frequency in adult patients with OIC compared to placebo. These studies also evaluated the safety profile of the medication [1].
Can patients with certain conditions use Movantik?
Movantik is generally not recommended for patients with a known or suspected gastrointestinal obstruction or in those with severe or active inflammatory bowel disease [1]. Patients should consult their healthcare provider to determine if Movantik is appropriate for their specific medical history and condition.
How is Movantik dosed?
The typical dose for Movantik is 25 mg taken orally once daily [1]. It is important to take the medication as prescribed by a healthcare professional.
What are the risks associated with Movantik?
The primary risks associated with Movantik include the potential for serious gastrointestinal adverse events, such as bowel obstruction or perforation, especially in patients with pre-existing gastrointestinal issues or those taking opioids for an extended period [1].
Where can I find more information on Movantik's patent status?
Detailed information on Movantik's patent status, including any litigation or expiry projections, is available on DrugPatentWatch.com [3].
Sources:
[1] https://www.movantik.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732843/
[3] https://drugpatentwatch.com/
[4] https://www.redhillbio.com/